EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Current status and hurdles for CAR-T cell immune therapy

Ruocong Zhao, Yuanbin Cui, Shanglin Li, Le Qin, Peng Li

Blood Science · 2019-10 · 1 (2) · 148-155

DOI: 10.1097/bs9.0000000000000025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Science, 2019-10. Verfasst von Ruocong Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine an…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T (CAR-T) cells have emerged as novel and promising immune therapies for the treatment of multiple types of cancer in patients with hematological malignancies. There are several key components critical for development and application of CAR-T therapy. First, the design of CAR vectors can considerably affect several aspects of the physiological functions of these T cells. Moreover, despite the wide use of γ-retrovirus and lentivirus in mediating gene transfer into T cells, optimal CAR delivery systems are also being developed and evaluated. In addition, several classes of mouse models have been used to evaluate the efficacies of CAR-T cells; however, each model has its own limitations. Clinically, although surprising complete remission (CR) rates were observed in acute lymphoblastic leukemia (ALL), lymphoma, and multiple myeloma (MM), there is still a lack of specific targets for acute myeloid leukemia (AML). Leukemia relapse remains a major challenge, and its mechanism is presently under investigation. Cytokine release syndrome (CRS) and neurotoxicity are life-threatening adverse effects that need to be carefully treated. Several factors that compromise the activities of anti-solid cancer CAR-T cells have been recognized, and further improvements targeting these factors are the focus of the development of novel CAR-T cells. Overcoming the current hurdles will lead to optimal responses of CAR-T cells, thus paving the way for their wide clinical application.

Schlagwörter

Stichwörter der Autor:innen

CancerChimeric antigen receptor T cellsImmune therapy

Autor:innen und Institutionen

  • Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.

Zitieren

APA

Zhao, R., Cui, Y., Li, S., Qin, L., & Li, P. (2019). Current status and hurdles for CAR-T cell immune therapy. Blood Science, 1(2), 148-155. https://doi.org/10.1097/bs9.0000000000000025

Vancouver

Zhao R, Cui Y, Li S, Qin L, Li P. Current status and hurdles for CAR-T cell immune therapy. Blood Science. 2019;1(2):148-155. doi:10.1097/bs9.0000000000000025

BibTeX
@article{Zhao2019,
  author = {Zhao, Ruocong and Cui, Yuanbin and Li, Shanglin and Qin, Le and Li, Peng},
  title = {Current status and hurdles for CAR-T cell immune therapy},
  journal = {Blood Science},
  year = {2019},
  volume = {1},
  number = {2},
  pages = {148--155},
  doi = {10.1097/bs9.0000000000000025}
}
Kostenlos starten →